Zhang W, Sun XQ, Peng XY. Macular ganglion cell complex injury in different stages of anterior ischemic optic neuropathy. World J Clin Cases 2021; 9(21): 5830-5839 [PMID: 34368302 DOI: 10.12998/wjcc.v9.i21.5830]
Corresponding Author of This Article
Xiao-Yan Peng, PhD, Doctor, Professor, Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, No. 17 Hougou Lane, Chongnei Street, Beijing 100005, China. drzhangwei2014@163.com
Research Domain of This Article
Ophthalmology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2021; 9(21): 5830-5839 Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.5830
Macular ganglion cell complex injury in different stages of anterior ischemic optic neuropathy
Wei Zhang, Xin-Quan Sun, Xiao-Yan Peng
Wei Zhang, Xiao-Yan Peng, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China
Wei Zhang, Beijing Aier Intech Eye Hospital, Beijing 100021, China
Xin-Quan Sun, China-Japanese Friendship Hospital, Beijing 100029, China
Author contributions: Sun XQ contributed to the conception of the study; Peng XY designed the work; Zhang W contributed to the acquisition of the data; all authors contributed to the analysis and interpretation of data; Zhang W drafted the initial manuscript; Sun XQ and Peng XY revised the manuscript critically for important intellectual content; All authors have read the manuscript and gave their final approval of the version to be published.
Institutional review board statement: This study was reviewed and approved by the Institutional Ethical Review Boards of Beijing Aier Intech Eye Hospital, Beijing, China.
Informed consent statement: Informed consent statement was waived.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yan Peng, PhD, Doctor, Professor, Beijing Ophthalmology and Visual Science Key Laboratory, Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, No. 17 Hougou Lane, Chongnei Street, Beijing 100005, China. drzhangwei2014@163.com
Received: January 1, 2021 Peer-review started: January 1, 2021 First decision: January 24, 2021 Revised: March 4, 2021 Accepted: June 17, 2021 Article in press: June 17, 2021 Published online: July 26, 2021 Processing time: 200 Days and 9.2 Hours
ARTICLE HIGHLIGHTS
Research background
Presently the changes of macular ganglion cell complex (mGCC) thickness were assessed for neuro-ophthalmology and mGCC atrophic injury caused by chiasma opticum, visual radiation, and visual cortical diseases. This study aimed to explore the mGCC injury at different stages in anterior ischemic optic neuropathy (AION) and the clinical significance.
Research motivation
The pathogenesis, clinical manifestations, and clinical treatments of AION are yet elusive. The spectral domain optical coherence tomography examination is objective and non-injurious and can be widely used in the clinical examination of the AION.
Research objectives
Through study, the mGCC injury was different at the stages in AION. The most severe ganglion cell layer + inner plexus layer thinning occurred early when potential neuroprotective or protective therapy must be provided before 3 wk to reduce retinal ganglion cells loss.
Research methods
Ganglion cell layer plus inner plexiform layer is acutely unaffected in the early inflammatory edema stage of the AION and provides a reliable method to measure the structure of retinal neurons using optical coherence tomography 3D segmentation.
Research results
The “subnormal eye” was put forward as a clinical phenomenon often observed by the authors during mGCC examination. The onset time of AION was defined as early stage (within 3 wk of onset), middle stage (course of disease of 3 wk to 2 mo), and late stage (course of disease > 2 mo).
Research conclusions
The ganglion cell layer + inner plexus layer segmentation measurement of the spectral domain optical coherence tomography was superior to RNFL thickness as a biomarker for early structural loss in nerve ophthalmology.
Research perspectives
The mGCC analysis can be widely used in the study of nerve ophthalmology.
